GRS is under clinical development by Innovative Pharmacology Research and currently in Phase I for Hypertension. According to GlobalData, Phase I drugs for Hypertension have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRS’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecule is under development for the treatment of stable angina, hypertension and parenchymal hemorrhage. It is an indolinone-3 derivative. The drug candidate is an anti platelet agent which is administered through oral route in the form of capsule. It acts by targeting soluble guanylate cyclase.
Innovative Pharmacology Research overview
Innovative Pharmacology Research (IPHAR) is a drug development company offering services in the fields of synthesis, analytical chemistry, pharmaceutical development, preclinical and clinical trials, document development, drug registration, IP protection, commercialization and investment attraction, and others. IPHAR is headquartered in Tomsk, Russia.
For a complete picture of GRS’s drug-specific PTSR and LoA scores, buy the report here.